Chloasma, oral contraceptives, and plasma immunoreactive beta-melanocyte-stimulating hormone

Smith, A.G.; Shuster, S.; Thody, A.J.; Peberdy, M.; Smith, A.G; Shuster, S; Thody, A.J; Peberdy, M

doi:10.1111/1523-1747.ep12492633

Home

>

Node

>

Subnode

Chloasma, oral contraceptives, and plasma immunoreactive beta-melanocyte-stimulating hormone

Smith, A.G.; Shuster, S.; Thody, A.J.; Peberdy, M.

Journal of Investigative Dermatology 68(4): 169-170

1977

ISSN/ISBN: 0022-202X

PMID: 845449

DOI: 10.1111/1523-1747.ep12492633

Document Number: 432859

Plasma immunoreactive beta-melanocyte stimulating hormone (beta-MSH) has been measured in patients taking a progestogen-only oral contraceptive and in patients taking combined estrogen-progestogen therapy, of whom some had chloasma. Plasma levels did not differ significantly from those in a group of age- and sex-matched controls. It is concluded that the pigmentation of chloasma is not due to increased plasma concentrations of immunoreactive beta-MSH.